Kyn-activated AhR produced by CAFs isolated from tumors is associated with tumor drug resistance, and it has been suggested that targeted inhibition of AhR may be a new strategy for the treatment of malignant tumors (44, 45). This evidence concerns the gene AHR and neoplasm.